Group 1 - The first extraordinary general meeting of shareholders for Suzhou Saifen Technology Co., Ltd. was held on September 3, 2025, at the company's R&D building in Suzhou Industrial Park [2] - The meeting was convened by the board of directors and chaired by Chairman Huang Xueying, utilizing a combination of on-site and online voting methods [2][3] - All resolutions presented at the meeting were ordinary resolutions and were approved by more than half of the voting rights held by attending shareholders [4][5] Group 2 - The meeting included the attendance of 7 out of 8 current directors, with one director absent due to other commitments [3] - The meeting's legal compliance was verified by Beijing Hairun Tianrui Law Firm, confirming that the procedures and voting results were valid [5]

Group 1 - The company, Saifen Technology, announced the convening of its first extraordinary general meeting of shareholders for 2025 on September 3, 2025 [2] - The meeting will review and approve multiple proposals, including the proposal for amendments [2]

证券代码：688758 证券简称：赛分科技 公告编号：2025-034 苏州赛分科技股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 9 月 3 日 （二） 股东会召开的地点：江苏省苏州工业园区集贤街 11 号赛分科技研发大楼 一楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 136,845,602 | | 普通股股东所持有表决权数量 | 136,845,602 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.8589 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.8589 | ...

北京海润天睿律师事务所 关于苏州赛分科技股份有限公司 2025 年第一次临时股东会的法律意见书 致：苏州赛分科技股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受苏州赛分科技股份有 限公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第一次临 时股东会，并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《公司章程》及其他相关法律、法规的规定， 就公司本次股东会的召集、召开程序、出席会议人员的资格、召集人资格、表决 程序及表决结果等有关事宜出具本法律意见书。 关于本法律意见书，本所及本所律师谨作如下声明： 1. 在本法律意见书中，本所及本所律师仅就本次股东会的召集及召开程序、 出席会议人员及召集人的资格、表决程序及表决结果进行核查和见证并发表法律 意见，不对本次股东会的议案内容及其所涉及的事实和数据的完整性、真实性和 准确性发表意见。 2. 本所及本所律师依据《证券法》《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则（试行）》等规定以及本法律意 ...

Group 1 - The core viewpoint of the news is that Sai Fen Technology has shown a decline in stock price while maintaining a stable financing balance, indicating potential investor interest despite market fluctuations [1][2]. - As of August 26, 2023, Sai Fen Technology's stock price decreased by 2.42%, with a trading volume of 77.14 million yuan and a net financing purchase of 546,900 yuan [1]. - The company's financing balance reached 50.15 million yuan, accounting for 5.84% of its market capitalization, suggesting a moderate level of leverage in its capital structure [1]. Group 2 - For the first half of 2023, Sai Fen Technology reported a revenue of 183 million yuan, representing a year-on-year growth of 19.76%, and a net profit attributable to shareholders of 53.66 million yuan, which is a 40.91% increase compared to the previous year [2]. - The number of shareholders decreased by 4.63% to 10,500, while the average number of circulating shares per shareholder increased by 4.86% to 3,779 shares [2]. - Since its A-share listing, Sai Fen Technology has distributed a total of 17.08 million yuan in dividends [3].

Core Points - The company is holding its first extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will include the review and voting on specific proposals, including the revision of the fundraising management system and the election of a non-independent director [6][7] Meeting Procedures - Shareholders must register 30 minutes before the meeting and present required documents to attend [1] - The meeting will follow a specific agenda, including the announcement of attendees and their voting rights, and will allow for shareholder questions and comments [2][3] - Voting will be conducted both on-site and online, with specific time frames for online voting [7][4] Proposals - Proposal 1 involves the revision of the company's fundraising management system, which has been approved by the board and is now presented for shareholder review [6] - Proposal 2 is for the election of HAO NI as a non-independent director following the retirement of a previous board member, with his qualifications detailed in an attached resume [7][10] Candidate Information - HAO NI has a strong background in biochemistry and business management, with extensive experience in various managerial roles at major companies [10][11] - He does not hold direct shares in the company but has indirect holdings through a fund, and he meets all legal requirements to serve as a director [11]

2025 年 9 月 苏州赛分科技股份有限公司 2025 年第一次临时股东会会议资料 目录 证券代码：688758 证券简称：赛分科技 苏州赛分科技股份有限公司 2025 年第一次临时股东会会议资料 | 2025 | 年第一次临时股东会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第一次临时股东会议程 | 3 | | 2025 | 年第一次临时股东会会议议案 | 5 | | | 议案一： | 关于修订《募集资金管理制度》的议案 5 | | | 议案二： | 关于补选非独立董事的议案 6 | 2025年第一次临时股东会会议须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》以及《苏州赛分科技股份有限公司 章程》（以下简称"《公司章程》"）、《苏州赛分科技股份有限公司股东会议事规则》 等相关规定，苏州赛分科技股份有限公司（以下简称"公司"）特制定 2025 年第 一次临时股东会会议须知： 一、 为保证本次会议的严肃性和正常秩序，切实维护股 ...

Group 1 - The core viewpoint of the news highlights that Mingyuan Investment has conducted research on a listed company, Sifen Technology, which is experiencing strong demand recovery in the biopolymer field, particularly driven by domestic substitution trends [1] - Sifen Technology's overall performance is expected to grow steadily in 2025, with significant year-on-year increases in the antibody and peptide sectors [1] - In Q2, Sifen Technology reported increased revenue but a decline in profit margins due to lower gross margins in the insulin and GLP-1 sectors, alongside intensified market competition [1] Group 2 - The domestic innovative drug business development trend is leading to increased market demand, accelerated domestic substitution, technological innovation upgrades, customized service development, and intensified industry competition [1] - Sifen Technology's overseas business is divided into analytical chromatography and industrial fillers, with main competitors being Cytiva and Thermo Fisher; the company’s advantages lie in its technology platform and customized services [1] - The trend of domestic substitution is irreversible, and entering overseas markets requires local companies to serve international markets [1] Group 3 - The utilization rate of the first phase of Sifen Technology's production capacity in Yangzhou is high, and the second phase, once completed, will be able to meet the demands of large customers [1] - The recombinant collagen market is experiencing a boom, and Sifen Technology is developing various MMC composite mode fillers suitable for multiple subtypes of recombinant humanized collagen purification [1] - The GLP-1 drug market has broad prospects, with significant sales growth in related filler products [1]

Group 1 - The core viewpoint of the news is that Sai Fen Technology has shown positive financial performance and market activity, with a notable increase in stock price and trading volume [1][2] - As of August 22, 2023, Sai Fen Technology's stock price increased by 4.24%, with a trading volume of 137 million yuan and a net financing purchase of 2.0263 million yuan [1] - The company has a total financing and securities balance of 43.8673 million yuan, which accounts for 5.12% of its circulating market value [1] Group 2 - For the first half of 2023, Sai Fen Technology achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76%, and a net profit attributable to shareholders of 53.6592 million yuan, up 40.91% year-on-year [2] - As of June 30, 2023, the number of shareholders of Sai Fen Technology was 10,500, a decrease of 4.63% from the previous period, while the average circulating shares per person increased by 4.86% to 3,779 shares [2] - The company has distributed a total of 17.075 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The stock price of Saifen Technology (688758) has increased by 5.5% to 20.15 yuan as of August 22, 2025, with a market capitalization of 8.392 billion yuan [1] Shareholder Changes - As of June 30, 2025, the number of shareholders for Saifen Technology is 10,500, a decrease of 508 from March 31, 2025, representing a reduction of 4.63% [2][5] - The average number of shares held per shareholder increased from 38,000 to 39,800, with an average holding value of 682,900 yuan [2] Performance Disclosure Highlights - For the first half of 2025, Saifen Technology reported a main revenue of 183 million yuan, a year-on-year increase of 19.77% [3][5] - The net profit attributable to shareholders reached 53.6592 million yuan, up 40.91% year-on-year [3][5] - The net profit after deducting non-recurring gains and losses was 46.5029 million yuan, reflecting a 22.08% increase year-on-year [3] - In Q2 2025, the company achieved a single-quarter main revenue of 99.0458 million yuan, a 30.81% year-on-year increase [3] - The single-quarter net profit attributable to shareholders was 29.9466 million yuan, up 112.05% year-on-year [3] - The debt ratio stands at 5.16%, with an investment income of 70,000 yuan and financial expenses of -735,010 yuan, while the gross profit margin is 70.6% [3] Company Announcements Summary - Saifen Technology plans to distribute a cash dividend of 0.026 yuan per share (before tax) to all shareholders, totaling approximately 10.828 million yuan, which accounts for 20.18% of the net profit attributable to shareholders for the first half of 2025 [4][5] - The second board meeting of the company for 2025 was held on August 16, 2025, where several resolutions, including the half-year report and profit distribution plan, were approved [4]